A pre-clinical organoid model to select suitable bladder cancer patients for targeting EZH2 treatment

被引：0
|
作者：
Zhao, H. [1 ]
Liao, J. [2 ]
Liu, K. [1 ]
Chen, X. [1 ]
Wu, H. [1 ]
Chiu, P. K-F [1 ]
Ng, C-F [1 ]
Teoh, J. Y-C [1 ]
机构：
[1] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Dept Chem Pathol, Hong Kong, Peoples R China
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0592
引用
收藏
页码：S1501 / S1501
页数：1
相关论文
共 50 条
  • [41] A novel memory-like NK cell CAR targeting the proximal mesothelin domain shows promising pre-clinical activity in ovarian cancer using cell lines, patient-derived organoid tumors, and xenograft mice
    Tarannum, Mubin
    Dinh, Khanhlinh
    Vergara, Juliana
    Ay, Oyku
    Hill, Sarah
    Romee, Rizwan
    CANCER RESEARCH, 2023, 83 (07)
  • [42] Establishment and pre-clinical test of trastzumab resistant HR-/HER2+breast cancer patient-derived xenograft model
    Ryu, Jin-Sun
    Cho, Ye Un
    Kong, Sun-Young
    Park, In Hae
    Sim, Sung Hoon
    Lee, Eun Gyeong
    An, Kyounghee
    Lee, Eun Sook
    Lee, Keun Seok
    CANCER SCIENCE, 2018, 109 : 962 - 962
  • [43] Pre-clinical evaluation of the PP2A inhibitor LB-100 for the treatment of lapatinib resistant HER2-positive breast cancer.
    Conlon, Neil
    McDermott, Martina
    Browne, Brigid
    Roche, Sandra
    O'Neill, Fiona
    Meiller, Justine
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Pre-clinical myocardial dysfunction is detected by strain/strain rate before conventional measures in patients undergoing adjuvant breast cancer treatment with trastuzumab (Herceptin ™)
    Hare, James L.
    Leano, Rode
    Jenkins, Carly
    Brown, Joseph
    Marwick, Thomas H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A134 - A134
  • [45] TILKINE-2: A NOVEL BEST-IN-CLASS TUMOR INFILTRATING LYMPHOCYTE (TIL) TARGETING ENGINEERED IL-2 WITH SUPERIOR PRE-CLINICAL EFFICACY AND SAFETY FOR IMMUNOTHERAPY OF CANCER
    Challa, Sreerupa
    Carnino, Jonathan
    Umana, Andrea
    Li, Yuesheng
    Xu, Jing
    Rui, Lingyun
    Hsieh, Yao-Te
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A899 - A899
  • [46] Pre-clinical development of a dopamine receptor 2, PD-1 and CD47 trispecific antibody for treatment of small cell lung cancer
    Yao, Shugang
    Cui, Yun
    Kazanats, Anna
    Gong, Liying
    Bonfils, Claire
    Hou, Dominic
    Chen, Emily
    Undzys, Elijus
    Toulouse, Jacynthe
    Krstic, Milica
    Zahreddine, Hiba
    Matos, Israel
    Zhou, Alex
    Moya-Torres, Aniel
    Wargachuk, Richard
    Gay, Carl
    Byers, Lauren
    Ngan, Gordon
    da Cruz, Luis
    Young, David
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [47] Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy
    Alain G. Musende
    Andy Eberding
    Catherine Wood
    Hans Adomat
    Ladan Fazli
    Antonio Hurtado-Coll
    William Jia
    Marcel B. Bally
    Emma Tomlinson Guns
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 1085 - 1095
  • [48] Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy
    Musende, Alain G.
    Eberding, Andy
    Wood, Catherine
    Adomat, Hans
    Fazli, Ladan
    Hurtado-Coll, Antonio
    Jia, William
    Bally, Marcel B.
    Guns, Emma Tomlinson
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (06) : 1085 - 1095
  • [49] A pre-cystectomy decision model to predict pathologic upstaging and oncologic outcomes in clinical stage T2 bladder cancer
    Daneshmand, Siamak
    Skinner, Eila C.
    Miranda, Gus
    Mitra, Anirban Pradip
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Pre-clinical potency of INK128, a highly potent TORC1/2 kinase inhibitor in the HER2 amplified breast cancer model
    De, Pradip K. R.
    Sun, Yuliang
    Wu, Hui
    Rommel, Christian
    Yi, Liu
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2012, 72
12345